RESEARCH ARTICLE

Analgesic Effect of Nebulized Versus Intravenous Fentanyl for Pain Relief of Limb Fracture: A Double-Blind Clinical Trial

Mohammadreza Maleki Verki, Kambiz Masoumi*, Hassan Motamed, Meisam Moezi, Arash Forouzan and Ala Bahrami

Department of Emergency Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Received: August 21, 2017 Revised: October 05, 2017 Accepted: October 20, 2017

Abstract:

Background:

More than half of the patients attending emergency centers need analgesics. Injectable analgesics are currently the most common pain control strategy, but entail complications. Fentanyl is one of the most commonly used pain-relief opiates available in various forms.

Objective:

The present study aims to compare analgesic effects of nebulized against intravenous fentanyl for controlling pain due to limb fracture.

Method:

The present double-blind clinical trial recruited 213 patients presenting with fractured limbs to emergency departments. The first group of patients received 1 micg/kg of intravenous fentanyl citrate from a solution of 50 micg/ml and 5 ml of normal saline in nebulized form (group A), and the second group intravenously received 5 ml of normal saline and 4 micg/kg of 50 micg/ml solution of fentanyl citrate in nebulized form, whose volume reached 5 ml with the addition of normal saline (group B). Then, pain level was frequently measured and compared in the two groups for 20 minutes.

Results:

The results obtained showed reduced pain level in both the groups. However, point-by-point comparison of pain in the two groups revealed significantly greater pain reduction in intravenous fentanyl group (P<0.001). The need for adjuvant pain relief medication was 8.3% in intravenous fentanyl group and 24% in nebulized fentanyl group, with a significant difference between the two groups (P=0.002).

Conclusion:

According to the results, although nebulized fentanyl is effective in controlling pain due to limb fracture, it was less effective than intravenous type, and unable to control pain in many cases.

Keywords: Fentanyl, Intravenous, Nebulized, Limb Fracture.

1. INTRODUCTION

Fentanyl Citrate is a mu-receptor stimulant synthetic opioid introduced about 50 years ago, and has been widely used as an analgesic for chronic and acute pain since 1990 [1]. The bioavailability and time to peak plasma concentration of fentanyl depend on dose and administration route. Analgesia may take effect one to two minutes after...
intravenous administration of fentanyl, while it may take 10 to 15 minutes in buccal and tranmucosal routes. In contrast, sublingual administration and nasal spray of the new high lipophilic and low potential irritability formula made for mucosal use causes analgesia in 5 to 10 minutes [2, 3]. Nebulized fentanyl reaches therapeutic levels as fast as intravenous fentanyl [4, 5]. Intravenous fentanyl is administered at a dose of 1 micg/kg. In fact, the intravenous fentanyl dosage of 1 micg/kg corresponds to 5 micg/kg of nebulated fentanyl due to bioavailability of 20%. Hence, nebulized type is administered at a dose of 5 micg/kg [6 - 9]. Like other injectable medications, intravenous fentanyl entails some side effects like as other opioids, and if the efficacy of other delivery routes can be confirmed for pain relief, they can be used instead of injectable fentanyl. As a non-invasive, fast and effective pain relief method, nebulized fentanyl has been studied as a replacement for injection method. In this method, medication is absorbed through lungs and enters pulmonary blood circulation. Many studies have compared analgesic effects of nebulized fentanyl with intravenous morphine, and have shown that nebulated fentanyl acts as effectively as IV opioids in reducing acute pain [9 - 12]. Yet, the analgesic effects of nebulized fentanyl compared to IV fentanyl are not known for pain relief. Thus, the present study was conducted with the aim to compare analgesic effects of nebulated and IV fentanyl in controlling pain of limb fracture.

2. MATERIALS AND METHODS

2.1. Study Design

The present double-blind clinical trial was conducted on 15 to 55 year-old patients presenting with limb fracture to the emergency department of Imam Khomeini Hospital in Ahvaz, Iran. Pain was measured through visual analogue scale (VAS) and patients with pain levels higher than 5 were included, and fentanyl was used to control their pain. Patients using some medication such as antipsychotic, sleeping, and sedative agents, tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine-oxidase inhibitors, opioid addicts, patients with underlying diseases, such as acute or chronic liver, kidney, or heart diseases, respiratory problems including infection of upper or lower respiratory system, chronic obstructive pulmonary disease, asthma, allergy, pregnancy, breastfeeding, and these contraindicated for fentanyl were excluded. In case of any significant difference between groups regarding gender, age, initial pain score and type of fractures, they were matched. The present study was registered at Iran's clinical trials registry system (IRCT2015082423748N1), and was approved by the ethics committee of Jundishapur University of Medical Sciences in Ahvaz (IR.AJUMS.REC.1394.136). All patients entered the present study after signing written informed consent forms.

2.2. Therapeutic Interventions

Sealed envelopes containing type of therapy were placed in the emergency room and were randomly assigned to the participants. Control group patients received 1 micg/kg of intravenous fentanyl from 50 micg/ml solution (Caspian, Tamin, Iran) and 5 ml of normal saline (Mashhad Samen, Iran) in nebulated form. Case group patients received 5 ml of normal saline intravenously and 4 micg/kg from 50 micg/ml solution of fentanyl in IV form, whose volume reached 5 ml with normal saline in nebulated form. In both groups, nebulized medication was administered with 6 lit/minute oxygen over 2 to 3 minutes, which is the time taken for administration of 5 ml of medication by nebulizer, and this was followed by slow intravenous administration over 2 minutes. Patients’ pain level was assessed at 0, 10, 15 and 20 minutes. If the pain level did not reduce by at least 3 points in 15 minutes using VAS, a second higher dose was administered according to the protocol containing 1 micg/kg IV fentanyl. Patients were able to withdraw from the present study at any time, but received treatment according to the routine protocol. Nebulized medication was prepared for patients using Beuerer nebulizer IH21, Germany. Air is blown through the medication at a pressure of 1/2 bars. The air flow forces medication particles out and mixes them with the air inside the nozzle. This product has a European standard of CE.

2.3. Statistical Analysis

Data obtained were first assessed in terms of descriptive indices, and then normally distributed quantitative data from two groups were compared using t and Mann-Whitney tests. All analyses were performed in SPSS-19 at a significance level of 0.05.

3. RESULTS

Of the 213 participating patients, 166 (77.9%) were men and 47 (22.1%) were women, with mean age 49.31±5.5 years. There were no withdrawals from the present study. Demographic details of all patients are presented in Table (1).
These results show the two groups matched in terms of mean age, gender and limb fractures. Table (1). The results obtained showed no significant difference in response to treatment between patients with upper and limb fractures. The results also showed no significant difference between the two groups in mean pain level before intervention (P=0.764). However, point-by-point comparison of pain level in the two groups revealed significantly greater pain reduction in intravenous fentanyl group (P<0.001) Fig. (1). The need for adjuvant pain relief medication was 8.3% in intravenous fentanyl group and 24% in nebulized fentanyl group Fig. (2), with a significant difference between the two groups (P=0.002). (Tables 1-2).

Table 1. Patients Characteristics.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Nebulized fentanyl</th>
<th>I.V fentanyl</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age(year)</td>
<td>51.31±3.5</td>
<td>47.31±7.5</td>
<td>0.979</td>
</tr>
<tr>
<td>Sex</td>
<td>Male: 104 patients</td>
<td>Male: 109 patients</td>
<td>0.102</td>
</tr>
<tr>
<td></td>
<td>Female: 86 (82.7%)</td>
<td>Female: 80 (73.4%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18 (17.3%)</td>
<td>29 (26.6%)</td>
<td></td>
</tr>
<tr>
<td>Limb</td>
<td>Upper 57 (54.8%)</td>
<td>Upper 63 (57.8%)</td>
<td>0.66</td>
</tr>
<tr>
<td></td>
<td>Lower 47 (45.2%)</td>
<td>Lower 46 (42.2%)</td>
<td></td>
</tr>
</tbody>
</table>

%: ratio of patients in each group

Fig. (1). pain level in the two groups.

Table 2. Comparison of drug efficacy in Groups A and B.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Time</th>
<th>Nebulized Fentanyl</th>
<th>I.V Fentanyl</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain score</td>
<td>Before intervention</td>
<td>7.5962</td>
<td>7.5413</td>
<td>0.764</td>
</tr>
<tr>
<td></td>
<td>10 min</td>
<td>5.6250</td>
<td>2.8257</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>15 min</td>
<td>3.9615</td>
<td>2.2936</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>20 min</td>
<td>3.6635</td>
<td>2.3303</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Need to Additional therapy</td>
<td>Yes</td>
<td>25(24%)</td>
<td>9(8.3%)</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>79(76%)</td>
<td>100(91.7%)</td>
<td></td>
</tr>
</tbody>
</table>
4. DISCUSSION

Seeking pain relief is the most common reason for patients attending emergency departments [12], such that the chief complaint of 60% of patients attending emergency department was pain, caused by trauma in 31% of cases [13]. Trauma-induced injuries are one of the most important problems in developing countries. The incidence of such injuries has dramatically increased in Iran in the recent years, and their mortality rate is the second leading cause of death [14].

According to the reports, 30% to 40% of patients attending emergency departments require analgesics in the first 30 minutes [15]. Although pain can easily be managed, however, it is sometimes difficult to control for the busy departments. Thus, many researchers are now seeking fast, effective, and safe analgesics. The use of intravenous analgesics is currently the most common pain-relief strategy in Iran [16]. Meanwhile, in addition to the stress imposed on patients, intravenous infusion of medications is time consuming and sometimes fails due to the absence of IV access. Studies report failure of 12% to 26% of IV infusions in adults, which is probably higher in children [17]. Fentanyl is a synthetic opioid that is administered in different ways, including intravenous infusion, buccal transmucosal, intranasal and nebulized [2]. Intravenous infusion is the most common administration route. However, because of the associated problems, efficacy of nebulized fentanyl has now been assessed, with promising results.

CONCLUSION

In the present study, the efficacy of nebulized and IV fentanyl in reducing pain due to limb fracture was assessed. The present study results showed that in the course of assessment (0 to 60 minutes after intervention) both methods successfully reduced pain, but pain relief was significantly greater in IV fentanyl group as compared to nebulized fentanyl. The present study results agree with those obtained in a study by Miner et al., who assessed the efficacy of IV and nebulized fentanyl in 41 patients with acute pain, and showed higher levels of pain relief in patients receiving IV as compared to nebulized fentanyl [6]. Some studies have shown conflicting results. Kamal et al. showed that 2 μg/kg of nebulized fentanyl had the same efficacy as 2 μg/kg of IV fentanyl in reducing abdominal pain [18]. In a clinical trial by Joel et al., 50 patients with abdominal pain were treated with IV and nebulized fentanyl in two groups, and no significant difference was observed between them in terms of pain relief level [4]. Singh et al. also compared different doses of nebulized fentanyl with 2 μg/kg of IV fentanyl in 90 patients with postoperative pain and showed that 4
mkg/kg of nebulized fentanyl is as effective as 2 mkg/kg of IV fentanyl [19]. The present study results also showed that pain control failure was significantly higher in patients receiving nebulized fentanyl as compared to those receiving IV fentanyl (24% V 3.8% respectively). Similar results were obtained in Miner et al. study that showed that 3 out of 5 failures occurred in nebulized fentanyl group [6]. Generally, the present study results show that although nebulized fentanyl is beneficial in controlling pain in patients with limb fracture, it has poorer efficacy as compared to IV fentanyl, and is unable to control pain in many cases. Comparison of nebulized and IV fentanyl in patients with limb fracture pain for the first time and large sample size were strong points in the present study, and not assessing different doses and side-effects of medication in the two groups were limitations of this study.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The present study was registered at Iran's clinical trials registry system (IRCT2015082423748N1), and was approved by the ethics committee of Jundishapur University of Medical Sciences in Ahvaz (IR.AJUMS.REC.1394.136). All patients entered the present study after signing written informed consent forms.

HUMAN AND ANIMAL RIGHTS
The reported experiments are accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2008 (http://www.wma.net/en/20activities/10ethics/10helsinki/)

CONFLICT OF INTEREST
The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS
This article was an extract from a postgraduate thesis by Dr. Bahrami, conducted in and funded by Ahvaz Jundishapur University of Medical Sciences.

REFERENCES


© 2017 Verki et al.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.